Literature DB >> 8857078

Biotransformation of caffeine by cDNA-expressed human cytochromes P-450.

H R Ha1, J Chen, S Krahenbuhl, F Follath.   

Abstract

OBJECTIVES: The biotransformation of caffeine has been studied in vitro using human cytochrome P-450 isoenzymes (CYPs) expressed in human B-lymphoblastoid cell lines, namely CYP1A1, 1A2, 2A6, 2B6, 2D6-Val, 2E1 and 3A4, and microsomal epoxide hydroxylase (EH). In addition, CYP2D6-Met was also studied, in which a valine in the wild type (CYP2D6-Val) has been replaced by a methionine due to a G to A mutation in position 112.
RESULTS: At caffeine 3 mmol center dot l-1, five CYPs (1A1, 1A2, 2D6-Met, 2E1 and 3A4) catalysed the biotransformation of caffeine. Among the enzymes studied, CYP1A2, which predominantly catalysed paraxanthine formation, had the highest intrinsic clearance (160 l center dot h-1 center dot mmol-1 CYP). Together with its high abundance in liver, it should be considered, therefore, to be the most important isoenzyme in caffeine metabolism. The affinity of caffeine for CYP1A1 was comparable to that of its homologue 1A2. CYP2D6-Met, which catalysed caffeine metabolism by demethylation and 8-hydroxylation, also had a relatively high intrinsic clearance (3.0 l center dot h-1 mmol-1 CYP), in particular for theophylline and paraxanthine formation, with kM values between 9-16 mmol center dot l-1. In contrast, the wild type, CYP2D6-Val, had no detectable activity. In comparison, CYP2E1 played a less important role in in vitro caffeine metabolism. CYP3A4 predominantly catalysed 8-hydroxylation with a kM value of 46 mmol center dot l-1 and an intrinsic clearance of 0.60 l center dot h-1 center dot mmol-1 CYP. Due to its high abundance in human liver, the latter CYP may contribute significantly to the in vivo formation of TMU.
CONCLUSION: The findings of this study indicate that i) microsomes from transfected human B-lymphoblastoid cell lines give results close to those obtained with microsomes isolated from human liver, ii) at least four CYP isoforms are involved in caffeine metabolism, iii) at a substrate concentration <0.1 mmol center dot l-1, CYP1A2 and 1A1 are the most important isoenzymes, iv) at higher concentrations the participation of other isoenzymes, in particular CYP3A4, 2E1 and possibly also CYP2D6-Met, are important in caffeine metabolism, and v) the nucleotide composition at position 1120 of CYP2D6 determines the activity of this isoenzyme in caffeine metabolism.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8857078     DOI: 10.1007/bf00226333

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  25 in total

1.  Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1.

Authors:  L Gu; F J Gonzalez; W Kalow; B K Tang
Journal:  Pharmacogenetics       Date:  1992-04

2.  Simultaneous assay of the methylxanthine metabolites of caffeine in plasma by high performance liquid chromatography.

Authors:  S Sved; D L Wilson
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1977-06

3.  Characterization of human lung microsomal cytochrome P-450 1A1 and its role in the oxidation of chemical carcinogens.

Authors:  T Shimada; C H Yun; H Yamazaki; J C Gautier; P H Beaune; F P Guengerich
Journal:  Mol Pharmacol       Date:  1992-05       Impact factor: 4.436

4.  Evidence for the involvement of several cytochromes P-450 in the first steps of caffeine metabolism by human liver microsomes.

Authors:  F Berthou; J P Flinois; D Ratanasavanh; P Beaune; C Riche; A Guillouzo
Journal:  Drug Metab Dispos       Date:  1991 May-Jun       Impact factor: 3.922

5.  Variability in caffeine metabolism.

Authors:  D M Grant; B K Tang; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1983-05       Impact factor: 6.875

6.  Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450.

Authors:  D Diaz; I Fabre; M Daujat; B Saint Aubert; P Bories; H Michel; P Maurel
Journal:  Gastroenterology       Date:  1990-09       Impact factor: 22.682

7.  Biotransformation of caffeine by microsomes from human liver. Kinetics and inhibition studies.

Authors:  D M Grant; M E Campbell; B K Tang; W Kalow
Journal:  Biochem Pharmacol       Date:  1987-04-15       Impact factor: 5.858

8.  Caffeine disposition after oral doses.

Authors:  M Bonati; R Latini; F Galletti; J F Young; G Tognoni; S Garattini
Journal:  Clin Pharmacol Ther       Date:  1982-07       Impact factor: 6.875

9.  Assessment of caffeine exposure: caffeine content of beverages, caffeine intake, and plasma concentrations of methylxanthines.

Authors:  A Lelo; J O Miners; R Robson; D J Birkett
Journal:  Clin Pharmacol Ther       Date:  1986-01       Impact factor: 6.875

10.  Biotransformation of caffeine in human liver microsomes from foetuses, neonates, infants and adults.

Authors:  C Cazeneuve; G Pons; E Rey; J M Treluyer; T Cresteil; G Thiroux; P D'Athis; G Olive
Journal:  Br J Clin Pharmacol       Date:  1994-05       Impact factor: 4.335

View more
  9 in total

Review 1.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

2.  Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine.

Authors:  Janne T Backman; Marika T Granfors; Pertti J Neuvonen
Journal:  Eur J Clin Pharmacol       Date:  2006-04-27       Impact factor: 2.953

3.  Induction of cytochrome P450 1A by cow milk-based formula: a comparative study between human milk and formula.

Authors:  Haibo Xu; Ratheishan Rajesan; Patricia Harper; Richard B Kim; Bo Lonnerdal; Mingdong Yang; Satoko Uematsu; Janine Hutson; Jo Watson-MacDonell; Shinya Ito
Journal:  Br J Pharmacol       Date:  2005-09       Impact factor: 8.739

4.  A re-evaluation and validation of ontogeny functions for cytochrome P450 1A2 and 3A4 based on in vivo data.

Authors:  Farzaneh Salem; Trevor N Johnson; Khaled Abduljalil; Geoffrey T Tucker; Amin Rostami-Hodjegan
Journal:  Clin Pharmacokinet       Date:  2014-07       Impact factor: 6.447

5.  Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children.

Authors:  Trevor N Johnson; Amin Rostami-Hodjegan; Geoffrey T Tucker
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

6.  Artemisinin and thiabendazole are potent inhibitors of cytochrome P450 1A2 (CYP1A2) activity in humans.

Authors:  Tashinga E Bapiro; Jane Sayi; Julia A Hasler; Mary Jande; Gerald Rimoy; Amos Masselle; Collen M Masimirembwa
Journal:  Eur J Clin Pharmacol       Date:  2005-10-29       Impact factor: 2.953

Review 7.  Potential implications of DMET ontogeny on the disposition of commonly prescribed drugs in neonatal and pediatric intensive care units.

Authors:  Siavosh Naji-Talakar; Sheena Sharma; Leslie A Martin; Derek Barnhart; Bhagwat Prasad
Journal:  Expert Opin Drug Metab Toxicol       Date:  2021-01-20       Impact factor: 4.481

8.  Multi-phase multi-layer mechanistic dermal absorption (MPML MechDermA) model to predict local and systemic exposure of drug products applied on skin.

Authors:  Nikunjkumar Patel; James F Clarke; Farzaneh Salem; Tariq Abdulla; Frederico Martins; Sumit Arora; Eleftheria Tsakalozou; Arran Hodgkinson; Omid Arjmandi-Tash; Sinziana Cristea; Priyanka Ghosh; Khondoker Alam; Sam G Raney; Masoud Jamei; Sebastian Polak
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2022-06-27

9.  Comparison of the metabolism of 10 chemicals in human and pig skin explants.

Authors:  C Géniès; E L Jamin; L Debrauwer; D Zalko; E N Person; J Eilstein; S Grégoire; A Schepky; D Lange; C Ellison; A Roe; S Salhi; R Cubberley; N J Hewitt; H Rothe; M Klaric; H Duplan; C Jacques-Jamin
Journal:  J Appl Toxicol       Date:  2018-10-21       Impact factor: 3.446

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.